Class of 2025
For lauded research contributions to human dendritic cell biology, including the development of Toll-like receptor agonist- and dendritic cell-based vaccines for cancer and infectious diseases, and for leading clinical trials integrating checkpoint immunotherapies and innovative immunoadjuvants to advance patient care.
*Full-length biography in development
[Institutional affiliations listed for Fellows reflect those held at the time of their induction into the AACR Academy.]